Drug Profile
Denifanstat - Sagimet Biosciences
Alternative Names: [14C]-TVB-2640; ASC 40; TVB-2640Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator 3-V Biosciences
- Developer Ascletis; Mayo Clinic; Sagimet Biosciences; University of Kentucky; University of Texas Health Science Center at San Antonio
- Class Antiacnes; Antineoplastics; Benzonitrile; Cyclobutanes; Hepatoprotectants; Piperidines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acne vulgaris; Glioblastoma
- Phase II Astrocytoma; Breast cancer; Non-alcoholic steatohepatitis; Non-small cell lung cancer
- Phase I Liver disorders; Prostate cancer
- No development reported Colorectal cancer; Solid tumours
Most Recent Events
- 25 Mar 2024 Sagimet Biosciences expects an end of phase II meeting with US FDA in Non-alcoholic steatohepatitis in first half of 2024
- 11 Mar 2024 Interim efficacy and adverse events data from a phase II in Acne vulgaris released by Ascletis
- 26 Feb 2024 Pharmacodynamics data from a preclinical trial in Prostate cancer presented at the ESMO Targeted Anticancer Therapies Congress (ESMO-2024)